92022-96-3

Upstream product

• 488-23-3 1,2,3,4-Tetramethylbenzene 
• 104-94-9 4-methoxy-aniline 
• 610-40-2 3,4-dinitro-chlorobenzene 
• 611-06-3 2,4-dichloronitrobenzene 

Downstream Products

• 79759-06-1 4-Chloro-N₂-(4-methoxyphenyl)benzene-1,2-diamine 
• 79759-69-6 6-chloro-1-(4-methoxyphenyl)-1,3-dihydro-2H-benzimidazol-2-one 
• 79759-70-9 5-Chloro-3-(4-methoxy-phenyl)-1-methyl-1,3-dihydro-benzoimidazol-2-one 
• 79759-20-9 [4-Chloro-2-(4-methoxy-phenylamino)-phenyl]-carbamic acid ethyl ester 
• 4793-90-2 5-methoxy-N-(4-methoxyphenyl)-2-nitro-aniline 
• 958264-02-3 8-chloro-10-(4-methoxyphenyl)-10H-benzo[g]pteridine-2,4-dione 
• 958264-08-9 8-chloro-10-(4-methoxyphenyl)-3-(3-pyrrolidin-1-ylpropyl)-10H-benzo[g]pteridine-2,4-dione 
• 958263-97-3 10-(4-methoxyphenyl)-3-(3-pyrrolidin-1-ylpropyl)-8-(3-pyrrolidin-1-ylpropylamino)-10H-benzo[g]pteridine-2,4-dione 

Relevant academic research and scientific papers

10H-BENZO(G)PTERDINE-2,4-DIONE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

This invention pertains generally to the field of G-quadruplex ligands, and more particularly, to certain 10H-benzo[g]pteridine-2,4-dione compounds ("BPD compounds"), as described herein, which, inter alia, (selectively) bind (and stabilize) G-quadruplexes. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) bind (and stabilize) G-quadruplexes, to inhibit telomerase, to regulate cell proliferation, and in the treatment of proliferative disorders, such as cancer. Formula (I):

RECEPTOR FUNCTION REGULATING AGENT

The present invention relates to a GPR40 receptor function regulator comprising a fused imidazole compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof. The GPR40 receptor funct

Trisubstituted isoalloxazines as a new class of G-quadruplex binding ligands: Small molecule regulation of c-kit oncogene expression

Herein, we report the design, synthesis, biophysical evaluation with primary biological data of 3,8,10-trisubstituted isoalloxazines as a new class of G-quadruplex binding ligands. We have developed a short and robust synthesis for trisubstituted isoalloxazines in good yields. The G-quadruplex binding and stabilization potential of isoalloxazines was assessed by surface plasmon resonance and fluorescence resonance energy transfer assay. The data revealed that these isoalloxazines bind and stabilize G-quadruplex DNA, but not duplex DNA, and exhibit potential for discriminating between DNA quadruplexes. Cell-based experiments using cell lines that express the proto-oncogene c-kit (MCF-7 and HGC-27) showed that such isoalloxazines can inhibit the expression of c-kit. Copyright

1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives

The present invention relates to 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives of the formula: STR1 to their preparation and to the pharmaceutical compositions in which they are present. These derivatives have an affinity for the vasopressin and oxytocin receptors.